Kostas Biliouris
Stock Analyst at Oppenheimer
(0.56)
# 4,303
Out of 5,088 analysts
445
Total ratings
38.9%
Success rate
-2.3%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Kostas Biliouris
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| KRRO Korro Bio | Reiterated: Buy | $22 | $13.86 | +58.73% | 20 | Oct 29, 2026 | |
| DYN Dyne Therapeutics | Downgraded: Hold | $15 | $16.98 | -11.66% | 6 | Oct 28, 2026 | |
| NRIX Nurix Therapeutics | Reiterated: Buy | $28 → $32 | $27.26 | +17.39% | 3 | Oct 13, 2026 | |
| PEPG PepGen | Reiterated: Buy | $15 | $2.53 | +492.89% | 4 | Oct 7, 2026 | |
| PRME Prime Medicine | Reiterated: Buy | $11 | $5.36 | +105.22% | 20 | Sep 25, 2026 | |
| EVMN Evommune | Reiterated: Buy | $50 → $26 | $6.31 | +312.04% | 4 | Sep 9, 2026 | |
| IRD Opus Genetics | Reiterated: Buy | $10 → $20 | $3.68 | +443.48% | 3 | Sep 9, 2026 | |
| TRDA Entrada Therapeutics | Reiterated: Buy | $23 | $4.84 | +375.21% | 5 | Sep 3, 2026 | |
| OVID Ovid Therapeutics | Reiterated: Buy | $9 | $2.45 | +267.35% | 2 | Aug 14, 2026 | |
| PRQR ProQR Therapeutics | Reiterated: Buy | $9 | $1.41 | +538.30% | 4 | Aug 14, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $56.25 | $9.03 | +522.93% | 3 | Aug 14, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $75 → $40 | $22.53 | +77.54% | 60 | Aug 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $37 → $35 | $19.32 | +81.16% | 38 | Aug 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $500 → $350 | $232.40 | +50.60% | 41 | Jul 31, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $21 | $11.08 | +89.53% | 4 | Jun 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $20 | $7.47 | +167.74% | 21 | Jun 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $70.82 | n/a | 12 | Sep 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $28.78 | n/a | 23 | Sep 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $56.00 | n/a | 31 | Sep 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $12.93 | n/a | 30 | Sep 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $44.90 | n/a | 27 | Sep 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $0.5388 | n/a | 4 | Sep 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $0.8217 | n/a | 9 | Sep 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $13.32 | n/a | 25 | Sep 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $2.58 | n/a | 5 | Sep 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $19.71 | n/a | 14 | Sep 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $75 | $54.11 | n/a | 20 | Sep 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $3.21 | n/a | 6 | Jan 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $77 | $318.78 | n/a | 1 | Jun 16, 2022 |
Korro Bio
Oct 29, 2026
Reiterated: Buy
Price Target: $22
Current: $13.86
Upside: +58.73%
Dyne Therapeutics
Oct 28, 2026
Downgraded: Hold
Price Target: $15
Current: $16.98
Upside: -11.66%
Nurix Therapeutics
Oct 13, 2026
Reiterated: Buy
Price Target: $28 → $32
Current: $27.26
Upside: +17.39%
PepGen
Oct 7, 2026
Reiterated: Buy
Price Target: $15
Current: $2.53
Upside: +492.89%
Prime Medicine
Sep 25, 2026
Reiterated: Buy
Price Target: $11
Current: $5.36
Upside: +105.22%
Evommune
Sep 9, 2026
Reiterated: Buy
Price Target: $50 → $26
Current: $6.31
Upside: +312.04%
Opus Genetics
Sep 9, 2026
Reiterated: Buy
Price Target: $10 → $20
Current: $3.68
Upside: +443.48%
Entrada Therapeutics
Sep 3, 2026
Reiterated: Buy
Price Target: $23
Current: $4.84
Upside: +375.21%
Ovid Therapeutics
Aug 14, 2026
Reiterated: Buy
Price Target: $9
Current: $2.45
Upside: +267.35%
ProQR Therapeutics
Aug 14, 2026
Reiterated: Buy
Price Target: $9
Current: $1.41
Upside: +538.30%
Aug 14, 2026
Reiterated: Buy
Price Target: $56.25
Current: $9.03
Upside: +522.93%
Aug 12, 2026
Downgraded: Hold
Price Target: $75 → $40
Current: $22.53
Upside: +77.54%
Aug 6, 2026
Reiterated: Buy
Price Target: $37 → $35
Current: $19.32
Upside: +81.16%
Jul 31, 2026
Reiterated: Buy
Price Target: $500 → $350
Current: $232.40
Upside: +50.60%
Jun 15, 2026
Reiterated: Buy
Price Target: $21
Current: $11.08
Upside: +89.53%
Jun 9, 2026
Initiated Coverage: Buy
Price Target: $20
Current: $7.47
Upside: +167.74%
Sep 25, 2025
Rated: Hold
Price Target: n/a
Current: $70.82
Upside: n/a
Sep 25, 2025
Rated: Hold
Price Target: n/a
Current: $28.78
Upside: n/a
Sep 25, 2025
Rated: Hold
Price Target: n/a
Current: $56.00
Upside: n/a
Sep 25, 2025
Rated: Hold
Price Target: n/a
Current: $12.93
Upside: n/a
Sep 25, 2025
Rated: Hold
Price Target: n/a
Current: $44.90
Upside: n/a
Sep 25, 2025
Rated: Hold
Price Target: n/a
Current: $0.5388
Upside: n/a
Sep 25, 2025
Rated: Hold
Price Target: n/a
Current: $0.8217
Upside: n/a
Sep 25, 2025
Rated: Hold
Price Target: n/a
Current: $13.32
Upside: n/a
Sep 25, 2025
Rated: Hold
Price Target: n/a
Current: $2.58
Upside: n/a
Sep 25, 2025
Rated: Hold
Price Target: n/a
Current: $19.71
Upside: n/a
Sep 23, 2025
Reiterated: Buy
Price Target: $75
Current: $54.11
Upside: n/a
Jan 29, 2024
Rated: Hold
Price Target: n/a
Current: $3.21
Upside: n/a
Jun 16, 2022
Initiated Coverage: Buy
Price Target: $77
Current: $318.78
Upside: n/a